Centrum Medyczne Medyk Sp. z o.o. — Clinical Trial Site

45 Registered trials

12 Currently recruiting

Organisation

Centrum Medyczne Medyk Sp. z o.o.

Location

Rzeszow, Poland

Identifier

ORG-100032970

Address

Ul. Fryderyka Szopena 1, 35-055, Poland

Departments

"Centrum Medycznym Medyk Przychodnia Al. Rejtana 53"
#PL10001:Gastrology
3003:Cardiology
Centrum Medyczne „Medyk"
Centrum Medyczne Medyk
Centrum Medyczne Medyk Sp. z o.o.
Department of Oncology
Gastroenterologia
Gastroenterology
n/a
NA
Neurology
Pion Onkologiczny
PL10005: gastroenterology
PL10015: Centrum Medyczne Medyk
PL10016: Centrum Medyczne Medyk
PL10018:Centrum Medyczne MEDYK
PL10023_Gastroenterology
Poradnia neurologiczna
Private Practice
Szpital Centrum Medycznego Medyk

Clinical trials at this site (45)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Randomized, Double-Blind, Placebo Controlled, Multi - Center, Phase 1b Study to Evaluate the Safety and Tolerability of LIV001 in Patients… Pending

2024-514520-16-00 mild-to-moderate active ulcerative colitis 3
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting

2023-508304-38-00 Ulcerative Colitis (UC) 4 2024-09-10
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting

2024-515023-11-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2026-01-22
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting

2025-520705-12-00 Colitis Ulcerative 4 2025-06-24
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Moderately to Severely Active Crohn’s Disease 6 2024-07-31
Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting

2022-501119-14-01 Ulcerative Colitis 4 2024-04-16
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting

2023-509179-18-00 Castration Resistant Prostate Cancer (CRPC) 1 2019-08-13
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn's Disease Ended

2023-504740-33-00 Fistulizing perianal Crohn's Disease 5 2022-11-22